167 related articles for article (PubMed ID: 38419324)
1. Ganodermanontriol Suppresses the Progression of Lung Adenocarcinoma by Activating CES2 to Enhance the Metabolism of Mycophenolate Mofetil.
Xie Q; Cao Z; You W; Cai X; Shen M; Yin Z; Jiang Y; Wang X; Ye S
J Microbiol Biotechnol; 2024 Feb; 34(2):249-261. PubMed ID: 38419324
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in IMPDH2, UGT2B7, and CES2 genes influence the risk of graft rejection in kidney transplant recipients taking mycophenolate mofetil.
Cilião HL; Camargo-Godoy RBO; Souza MF; Zanuto A; Delfino VDA; Cólus IMS
Mutat Res Genet Toxicol Environ Mutagen; 2018 Dec; 836(Pt B):97-102. PubMed ID: 30442353
[TBL] [Abstract][Full Text] [Related]
3. Ganodermanontriol (GDNT) exerts its effect on growth and invasiveness of breast cancer cells through the down-regulation of CDC20 and uPA.
Jiang J; Jedinak A; Sliva D
Biochem Biophys Res Commun; 2011 Nov; 415(2):325-9. PubMed ID: 22033405
[TBL] [Abstract][Full Text] [Related]
4. Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
Fujiyama N; Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Habuchi T; Suzuki T
Xenobiotica; 2009 May; 39(5):407-14. PubMed ID: 19274604
[TBL] [Abstract][Full Text] [Related]
5. Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil.
Fujiyama N; Miura M; Kato S; Sone T; Isobe M; Satoh S
Drug Metab Dispos; 2010 Dec; 38(12):2210-7. PubMed ID: 20823294
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability.
Koehl GE; Wagner F; Stoeltzing O; Lang SA; Steinbauer M; Schlitt HJ; Geissler EK
Transplantation; 2007 Mar; 83(5):607-14. PubMed ID: 17353782
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolic acid is a drug with the potential to be repurposed for suppressing tumor growth and metastasis in osteosarcoma treatment.
Klangjorhor J; Chaiyawat P; Teeyakasem P; Sirikaew N; Phanphaisarn A; Settakorn J; Lirdprapamongkol K; Yama S; Svasti J; Pruksakorn D
Int J Cancer; 2020 Jun; 146(12):3397-3409. PubMed ID: 31609477
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate Mofetil Alone and in Combination with Tacrolimus Inhibits the Proliferation of HT-29 Human Colonic Adenocarcinoma Cell Line and Might Interfere with Colonic Tumorigenesis.
Ling G; Lamprecht S; Shubinsky G; Osyntsov L; Yerushalmi B; Pinsk I; Pinsk V; Ling E
Anticancer Res; 2018 Jun; 38(6):3333-3339. PubMed ID: 29848681
[TBL] [Abstract][Full Text] [Related]
9. Everolimus and mycophenolate mofetil sensitize human pancreatic cancer cells to gemcitabine in vitro: a novel adjunct to standard chemotherapy?
Tuncyurek P; Mayer JM; Klug F; Dillmann S; Henne-Bruns D; Keller F; Stracke S
Eur Surg Res; 2007; 39(6):380-7. PubMed ID: 17700025
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle formulation of mycophenolate mofetil achieves enhanced efficacy against hepatocellular carcinoma by targeting tumour-associated fibroblast.
Yang Z; Zhang L; Zhu H; Zhou K; Wang H; Wang Y; Su R; Guo D; Zhou L; Xu X; Song P; Zheng S; Xie H
J Cell Mol Med; 2021 Apr; 25(7):3511-3523. PubMed ID: 33713546
[TBL] [Abstract][Full Text] [Related]
11. IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells.
Takebe N; Cheng X; Fandy TE; Srivastava RK; Wu S; Shankar S; Bauer K; Shaughnessy J; Tricot G
Mol Cancer Ther; 2006 Feb; 5(2):457-66. PubMed ID: 16505121
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients.
Ohmann EL; Burckart GJ; Brooks MM; Chen Y; Pravica V; Girnita DM; Zeevi A; Webber SA
J Heart Lung Transplant; 2010 May; 29(5):509-16. PubMed ID: 20061166
[TBL] [Abstract][Full Text] [Related]
13. Carboxylesterase 2 induces mitochondrial dysfunction via disrupting lipid homeostasis in oral squamous cell carcinoma.
Chen X; Liu Q; Chen Y; Wang L; Yang R; Zhang W; Pan X; Zhang S; Chen C; Wu T; Xia J; Cheng B; Chen X; Ren X
Mol Metab; 2022 Nov; 65():101600. PubMed ID: 36113774
[TBL] [Abstract][Full Text] [Related]
14. Ganodermanontriol inhibits expression of special AT rich sequence binding protein 1 gene in human hepatocellular carcinoma.
Xu C; Guo H; Kong D; Pang D; Ding Y
J Cancer Res Ther; 2018 Dec; 14(Supplement):S964-S968. PubMed ID: 30539830
[TBL] [Abstract][Full Text] [Related]
15. Tanshinone IIA suppresses the progression of lung adenocarcinoma through regulating CCNA2-CDK2 complex and AURKA/PLK1 pathway.
Li Z; Zhang Y; Zhou Y; Wang F; Yin C; Ding L; Zhang S
Sci Rep; 2021 Dec; 11(1):23681. PubMed ID: 34880385
[TBL] [Abstract][Full Text] [Related]
16. CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop.
Chen Y; Capello M; Rios Perez MV; Vykoukal JV; Roife D; Kang Y; Prakash LR; Katayama H; Irajizad E; Fleury A; Ferri-Borgogno S; Baluya DL; Dennison JB; Do KA; Fiehn O; Maitra A; Wang H; Chiao PJ; Katz MHG; Fleming JB; Hanash SM; Fahrmann JF
Mol Metab; 2022 Feb; 56():101426. PubMed ID: 34971802
[TBL] [Abstract][Full Text] [Related]
17. Expression of IMPDH mRNA after mycophenolate administration in male volunteers.
Kim S; Lee W; Chun S; Um TH; Min WK
Biomed Res Int; 2014; 2014():870209. PubMed ID: 25105143
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil attenuates concanavalin A-induced acute liver injury through modulation of TLR4/NF-κB and Nrf2/HO-1 pathways.
Serrya MS; Zaghloul MS
Pharmacol Rep; 2020 Aug; 72(4):945-955. PubMed ID: 32048261
[TBL] [Abstract][Full Text] [Related]
19. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.
Xu G; Zhang W; Ma MK; McLeod HL
Clin Cancer Res; 2002 Aug; 8(8):2605-11. PubMed ID: 12171891
[TBL] [Abstract][Full Text] [Related]
20. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells.
Pratt SE; Durland-Busbice S; Shepard RL; Heinz-Taheny K; Iversen PW; Dantzig AH
Clin Cancer Res; 2013 Mar; 19(5):1159-68. PubMed ID: 23325581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
